Impact BioMedical EBIT

The latest EBIT for IBO is $2.1M as of June 2026. That compares with $-37M in the prior-year period — up 105.5% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Impact BioMedical's historical trend and sector peers before judging valuation or financial health.

Over the past year, IBO's EBIT moved from $-37M to $2.1M — a 105.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Impact BioMedical's operating scale or balance-sheet position.

Against Healthcare companies, IBO currently prints $2.1M for EBIT, while the sector average sits near $23B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Impact BioMedical's growth, margins, and balance sheet.

A EBIT figure of $2.1M for IBO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting IBO's EBIT ($2.1M), review year-over-year change from $-37M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.